Valneva : T1 décevant lié à des contraintes d’approvisionnement – Guidance confirmée
>En dessous de attentes en topline et bottom line - Les revenus T1 sont en baisse de 2% à 32.8 M€ (-24% vs css) avec des ventes de produits stables à 32.1 M€ (-21% vs css). Cette performance décevante s’explique principalement par des problèmes d'approvisionnement sur Ixiaro qui ressort en baisse de 5% (-34% vs css). Dukoral affiche une croissance de 10% à 11.3 M€ (+18% vs css) soutenue par la reprise du marché du voyageur. Comme prévu, la distribution pour tiers (-9%...Valneva, together with its subsidiaries, is focused on vaccine development and antibody discovery. Co. generates revenue from both its marketed product, a vaccine for the prevention of Japanese encephalitis (IXIARO®/JESPECT®), commercial partnerships around a portfolio of product candidates and licensed technology platforms (EB66® cell line, VIVA,Screen antibody discovery technology, and the IC31® adjuvant) developed by Co. Related business activities include product research and development, regulatory and clinical activities, manufacturing of commercial product and advanced clinical product candidates, as well as administrative, corporate development, and marketing and sales activities.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.